Management of TKI Therapies in Integrated Delivery Network (IDN) Pharmacies 2022
Perspectives on drivers in treatment decisions in the management of hepatocellular carcinoma/renal cell carcinoma (HCC/RCC)
National – February 28, 2022
Faculty Chair
Bhavesh Shah, RPh, BCOP
Boston Medical Center
More Information
- Virtual series
- The group of advisors comprised 16 clinical pharmacists, nurse practitioners, and/or pharmacy managers from 11 states across the US
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on current treatment practices and future considerations for treatment of RCC and HCC
- Insights on the following therapies were obtained
- Management of TKI therapies in solid tumors
- Patient management within IDN pharmacies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 16 clinical pharmacists, nurse practitioners, and/or pharmacy managers from 11 states across the US
